1. Naylor MD, Karlawish JH, Arnold SE, et al. Advancing Alzheimer’s disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. Alzheimers Dement 2012;8: 445–452.

2. Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007;20: 380–385.

3. Thies W, Bleiler L; Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 2013;9: 208–245.

4. Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer’s disease: uncovering the secrets of secretases. Curr Opin Neurobiol 2001;11: 585–590.

5. Panza F, Solfrizzi V, Frisardi V, et al. Disease-modifying approach to the treatment of Alzheimer’s disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 2009;26: 537–555.

6. Panza F, Logroscino G, Imbimbo BP, Solfrizzi V. Is there still any hope for amyloid-based immunotherapy for Alzheimer’s disease? Curr Opin Psychiatry 2014;27: 128–137.

7. Frisardi V, Solfrizzi V, Imbimbo BP, et al. Towards disease-modifying treatment of Alzheimer’s disease: drugs targeting β-amyloid. Curr Alzheimer Res 2010;7: 40–55.

8. Solfrizzi V, Capurso C, D’Introno A, et al. Lifestyle-related factors in predementia and dementia syndromes. Expert Rev Neurother 2008;8: 133–158.

9. Peters R. The prevention of dementia. Int J Geriatr Psychiatry 2009;24: 452–458.

10. de la Torre JC (2010). Alzheimer’s disease is incurable but preventable. J Alzheimers Dis 2010;20: 861–870.

11. Solfrizzi V, Panza F, Frisardi V, et al. Diet and Alzheimer’s disease risk factors or prevention: the current evidence. Expert Rev Neurother 2011;11: 677–708

12. Panza F, Solfrizzi V, Logroscino G, et al. Current epidemiological approaches to the metabolic-cognitive syndrome. J Alzheimers Dis 2012;30 Suppl 2: S31–75

13. Richard E, Moll van Charante EP, van Gool WA. Vascular risk factors as treatment target to prevent cognitive decline. J Alzheimers Dis 2012;32: 733–740.

14. Solfrizzi V, Panza F. Mediterranean diet and cognitive decline. A lesson from the whole-diet approach: what challenges lie ahead? J Alzheimers Dis 2014;39: 283–286.

15. Grant WB. Dietary links to Alzheimer’s disease: 1999 Update. J Alzheimers Dis 1999;1: 197–201.

16. Solfrizzi V, Panza F, Capurso A. The role of diet in cognitive decline. J Neural Transm 2003;110: 95–110.

17. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer’s disease. Lancet Neurol 2004;3: 579–587.

18. Luchsinger JA, Noble JM, Scarmeas N. Diet and Alzheimer’s disease. Curr Neurol Neurosci Rep 2007;7: 366–372.

19. Sofi F, Macchi C, Abbate R, Gensini GF, Casini A. Effectiveness of the Mediterranean diet: can it help delay or prevent Alzheimer’s disease? J Alzheimers Dis 2010;20: 795–801.

20. Cunnane SC, Plourde M, Pifferi F, Bégin M, Féart C, Barberger-Gateau P. Fish, docosahexaenoic acid and Alzheimer’s disease. Prog Lipid Res 2009;48: 239–256.

21. Solfrizzi V, Frisardi V, Capurso C, et al. Dietary fatty acids in dementia and predementia syndromes: Epidemiological evidence and possible underlying mechanisms. Ageing Res Rev 2010;9: 184–199.

22. Loef M, Walach H. Fruit, vegetables and prevention of cognitive decline or dementia: a systematic review of cohort studies. J Nutr Health Aging 2012;16: 626–630.

23. Parrott MD, Greenwood CE (2007) Dietary influences on cognitive function with aging. From high-fat diets to healthful eating. Ann N Y Acad Sci 2007;1114: 389–397.

24. Eters R, Peters J, Warner J, Beckett N, Bulpitt C. Alcohol, dementia and cognitive decline in the elderly. a systematic review. Age Ageing 2008;37: 505–512.

25. Panza F, Frisardi V, Seripa D, et al. Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective? Int J Geriatr Psychiatry. 2012;27: 1218–1238.

26. Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean diet, cognitive function, and dementia: a systematic review. Epidemiology 2013;24: 479–489.

27. Psaltopoulou T, Sergentanis TN, Panagiotakos DB, Sergentanis IN, Kosti R, Scarmeas N. Mediterranean diet and stroke, cognitive impairment, depression: A meta-analysis. Ann Neurol 2013;74: 580–591.

28. Singh B, Parsaik AK, Mielke MM, et al. Association of Mediterranean diet with mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 2014;39: 271–282.

29. Yoshimura H. The potential of caffeine for functional modification from cortical synapses to neuron networks in the brain. Curr Neuropharmacol 2005;3: 309–316.

30. Lopez-Garcia E, Rodriguez-Artalejo F, Rexrode KM, Logroscino G, Hu FB, van Dam RM. Coffee consumption and risk of stroke in women. Circulation 2009;119: 1116–1123.

31. Ascherio A, Chen H. Caffeinated clues from epidemiology of Parkinson’s disease. Neurology 2003;61(11 Suppl 6): S51–54.

32. Beghi E, Pupillo E, Messina P, et al.; EURALS Group. Coffee and amyotrophic lateral sclerosis: a possible preventive role. Am J Epidemiol 2011;174: 1002–1008

33. Barranco Quintana JL, Allam MF, Serrano Del Castillo A, Fernandez-Crehuet Navajas R. Alzheimer’s disease and coffee: a quantitative review. Neurol Res 2007;29: 91–95.

34. Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N. Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis 2010;20 Suppl 1: S187–204.

35. Cao C, Cirrito JR, Lin X, et al. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer’s disease transgenic mice. J Alzheimers Dis 2009;17: 681–697.

36. Arendash GW, Schleif W, Rezai-Zadeh K, et al. Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 2006;142: 941–952.

37. Vila-Luna S, Cabrera-Isidoro S, Vila-Luna L, et al. Chronic caffeine consumption prevents cognitive decline from young to middle age in rats, and is associated with increased length, branching, and spine density of basal dendrites in CA1 hippocampal neurons. Neuroscience 2012;202: 384–395.

38. Prasanthi JR, Dasari B, Marwarha G, et al. Caffeine protects against oxidative stress and Alzheimer’s disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic Biol Med 2010;49: 1212–1220.

39. Chen X, Ghribi O, Geiger JD. Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer’s and Parkinson’s diseases. J Alzheimers Dis 2010;20: S127–141.

40. Giesbrecht T, Rycroft JA, Rowson MJ, De Bruin EA. The combination of L-theanine and caffeine improves cognitive performance and increases subjective alertness. Nutr Neurosci 2010;13: 283–290.

41. Jarvis MJ. Does caffeine intake enhance absolute levels of cognitive performance. Psychopharmacology (Berl) 1993;110: 45–52.

42. Johnson-Kozlow M, Kritz-Silverstein D, Barrett-Connor E, Morton D. Coffee consumption and cognitive function among older adults. Am J Epidemiol 2002;156: 842–850.

43. Kuriyama S, Hozawa A, Ohmori K, et al. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am J Clin Nutr 2006;83: 355–361.

44. Ng TP, Feng L, Niti M, Kua EH, Yap KB. Tea consumption and cognitive impairment and decline in older Chinese adults. Am J Clin Nutr 2008;88: 224–231.

45. Chin AV, Robinson DJ, O’Connell H, et al. Vascular biomarkers ofvcognitive performance in a community-based elderly population: the Dublin Healthy Ageing study. Age Ageing 2008;37: 559–564.

46. Nurk E, Refsum H, Drevon CA, et al. Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J Nutr 2009;139: 120–127.

47. Huang CQ, Dong BR, Zhang YL, Wu HM, Liu QX. Association of cognitive impairment with smoking, alcohol consumption, tea consumption, and exercise among Chinese nonagenarians/centenarians. Cogn Behav Neurol 2009;22: 190–196.

48. Corley J, Jia X, Kyle JA, et al. Caffeine consumption and cognitive function at age 70: The Lothian Birth Cohort 1936 Study. Psychosom Med 2010;72: 206–214.

49. Wu MS, Lan TH, Chen CM, Chiu HC, Lan TY. Socio-demographic and health-related factors associated with cognitive impairment in the elderly in Taiwan. BMC Public Health 2011;11: 22.

50. Valls-Pedret C, Lamuela-Raventós RM, Medina-Remón A, et al. Polyphenol-rich foods in the Mediterranean diet are associated with better cognitive function in elderly subjects at high cardiovascular risk. J Alzheimers Dis 2012;29: 773–782.

51. Lammi UK, Kivela SL, Nissinen A, Punsar S, Puska P, Karvonen M. Mental disability among elderly men in Finland: prevalence, predictors and correlates. Acta Psychiatr Scand 1989;0: 459–468.

52. van Boxtel MP, Schmitt JA, Bosma H, Jolles J. The effects of habitual caffeine use on cognitive change: a longitudinal perspective. Pharmacol Biochem Behav 2003;75: 921–927.

53. van Gelder B, Buijsse B, Tijhuis M, et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: The FINE Study. Eur J Clin Nutr 2007;61: 226–232.

54. Ritchie K, Carriere I, de Mendonca A, et al. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 2007;69: 536–545.

55. Laitala V, Kaprio J, Koskenvuo M, Raiha I, Rinne J, Silventoinen K. Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr 2009;90: 640–646.

56. Santos C, Lunet N, Azevedo A, de Mendonca A, Ritchie K, Barros H. Caffeine intake is associated with a lower risk of cognitive decline: A cohort study from Portugal. J Alzheimers Dis 2010;20 Suppl 1: S175–185.

57. Arab L, Biggs ML, O’Meara ES, Longstreth WT, Crane PK, Fitzpatrick AL. Gender differences in tea, coffee, and cognitive decline in the elderly: the Cardiovascular Health Study. J Alzheimers Dis 2011;27: 553–566.

58. Gelber RP, Petrovitch H, Masaki KH, Ross GW, White LR. Coffee intake in midlife and risk of dementia and its neuropathologic correlates. J Alzheimers Dis 2011;23: 607–615.

59. Feng L, Li J, Ng TP, Lee TS, Kua EH, Zeng Y. Tea drinking and cognitive function in oldest-old Chinese. J Nutr Health Aging 2012;16: 754–758.

60. Vercambre MN, Berr C, Ritchie K, Kang JH. Caffeine and cognitive decline in elderly women at high vascular risk. J Alzheimers Dis 2013;35: 413–421.

61. Cao C, Loewenstein DA, Lin X, Zhang C, et al. High Blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis 2012;30: 559–572.

62. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer’s disease in Australia. Neurology 1990;40: 1698–1707.

63. Maia L, de Mendonça A. Does caffeine intake protect from Alzheimer’s disease? Eur J Neurol 2002;9: 377–382.

64. Tyas SL, Manfreda J, Strain LA, Montgomery PR. Risk factors for Alzheimer’s disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol 2001;30: 590–597.

65. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156: 445–453.

66. Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ. Midlife dietary intake of antioxidants and risk of late-life incident dementia: The Honolulu-Asia Aging Study. Am J Epidemiol 2004;159: 959–967.

67. Dai Q, Borenstein AR, Wu Y, Jackson JC, Larson EB. Fruit and vegetable juices and Alzheimer’s disease: The Kame Project. Am J Med 2006;119: 751–759.

68. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis 2009;16: 85–91.

69. Arab L, Khan F, Lam H. Epidemiologic evidence of a relationship between tea, coffee, or caffeine consumption and cognitive decline. Adv Nutr 2013;4: 115–122.

70. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83–133.

71. Prediger RD, Batista LC, Takahashi RN. Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. Neurobiol Aging 2005;26: 957–964.

72. Dall’Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25–35)-induced cognitive deficits in mice. Exp Neurol 2007;203: 241–245.

73. Costenla AR, Cunha RA, de Mendonça A. Caffeine, adenosine receptors, and synaptic plasticity. J Alzheimers Dis 2010;20 Suppl 1: S25–34.

74. Tebano MT, Martire A, Rebola N, et al. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects. J Neurochem 2005;95: 1188–1200.

75. Normile HJ, Gaston S, Johnson G, Barraco RA. Activation of adenosine A1 receptors in the nucleus accumbens impairs inhibitory avoidance memory. Behav Neural Biol 1994;62: 163–166.

76. Ohno M, Watanabe S. Working memory failure by stimulation of hippocampal adenosine A1 receptors in rats. Neuroreport 1996;7: 3013–3016.

77. Pereira GS, Rossato JI, Sarkis JJ, Cammarota M, Bonan CD, Izquierdo I. Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat. Neurobiol Learn Mem 2005;83: 217–223.

78. Cunha RA, Agostinho PM. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J Alzheimers Dis 2010;20 Suppl 1: S95–116.

79. Arendash GW, Mori T, Cao C, et al. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer’s disease mice. J Alzheimers Dis 2009;17: 661–680.

80. Zeitlin R, Patel S, Burgess S, Arendash GW, Echeverria V. Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer’s transgenic mice. Brain Res 2011;1417: 127–136.

81. Dragicevic N, Delic V, Cao C, et al. Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer’s mice and cells. Neuropharmacology 2012;63: 1368–1379.

82. Cao C, Wang L, Lin X, et al. Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer’s mice. J Alzheimers Dis 2011;25: 323–335.

83. Ritchie K, Artero S, Portet F, et al. Caffeine, cognitive functioning, and white matter lesions in the elderly: establishing causality from epidemiological evidence. J Alzheimers Dis 2010;20 Suppl 1: S161–6.

84. de Mendonça A, Sebastião AM, Ribeiro JA. Adenosine: Does it have a neuroprotective role after all? Brain Res Rev 2000;33: 258–274.

85. Duarte JMN, Agostinho PM, Carvalho RA, Cunha RA. Caffeine consumption prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of NONcZNO10/LTJ mice. PLoS ONE 7: e21899, 2012.

86. Biessels GJ. Caffeine, diabetes, cognition, and dementia. J Alzheimers Dis 2010;20 Suppl 1: S143–50.

87. de Valk HW. Magnesium in diabetes mellitus. Neth J Med 1999;54: 139–146.

88. Smith AP. Caffeine at work. Hum Psychopharmacol 2005;20: 441–445.

89. Kempf K, Herder C, Erlund I, et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr 2010;91: 950–957.

90. Abreu RV, Silva-Oliveira EM, Moraes MF, Pereira GS, Moraes-Santos T. Chronic coffee and caffeine ingestion effects on the cognitive function and antioxidant system of rat brains. Pharmacol Biochem Behav 2011;99: 659–664.

91. Lucas M, Mirzaei F, Pan A, et al. Coffee, caffeine, and risk of depression among women. Arch Intern Med 2011;171: 1571–1578.

92. Beaudreau SA, O’Hara R. The association of anxiety and depressive symptoms with cognitive performance in community-dwelling older adults. Psychol Aging 2009;24: 507–512.

93. Benowitz NL, Hall SM, Modin G. Persistent increase in caffeine concentrations in people who stop smoking. BMJ 1989;298: 1075–1076.

94. Santos AC, Barros H. Smoking patterns in a community sample of Portuguese adults, 1999–2000. Prev Med 2004;38: 114–119.

95. Higdon JV, Frei B. Coffee and health: A review of recent human research. Crit Rev Food Sci Nutr 2006;46: 101–123.

96. Ranheim T, Halvorsen B. Coffee consumption and human health–beneficial or detrimental?–mechanisms for effects of coffee consumption on different risk factors for cardiovascular disease and type 2 diabetes mellitus. Mol Nutr Food Res 2005;49: 274–284.

97. Svilaas A, Sakhi AK, Andersen LF, et al. Intakes of antioxidants in coffee, wine, and vegetables are correlated with plasma carotenoids in humans. J Nutr 2004;134: 562–567.

98. Jee SH, He J, Appel LJ, Whelton PK, Suh I, Klag MJ. Coffee consumption and serum lipids: A meta-analysis of randomized controlled clinical trials. Am J Epidemiol 2001;153: 353–362.

99. Sudano I, Binggeli C, Spieker L, et al. Cardiovascular effects of coffee: Is it a risk factor? Prog Cardiovasc Nurs 2005;20: 65–69.

100. Du Y, Melchert HU, Knopf H, Braemer-Hauth M, Gerding B, Pabel E. Association of serum caffeine concentrations with blood lipids in caffeine-drug users and nonusers–results of German national health surveys from 1984 to 1999. Eur J Epidemiol 2005;20: 311–316.

101. Song J, Xu H, Liu F, Feng L. Tea and cognitive health in late life: current evidence and future directions. J Nutr Health Aging 2012;16: 31–34.

102. Cabrera C, Artacho R, Gimenez R. Beneficial effects of green tea — a review. J Am Coll Nutr 2006;25: 79–99.

103. Gramza-Michalowska A. Caffeine in tea camellia sinensis — content, absorption, benefits and risks of consumption. J Nutr Health Aging 2014;18: 143–149.

104. Ng TP, Aung KC, Feng L, Feng L, Nyunt MS, Yap KB. Tea consumption and physical function in older adults: a cross-sectional study. J Nutr Health Aging 2014;18: 161–166.

105. Park SK, Jung IC, Lee WK, et al. A combination of green tea extract and l-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study. J Med Food 2011;14: 334–343.